Dyadic International (DYAI) Asset Utilization Ratio (2019 - 2026)
Dyadic International (DYAI) posted Asset Utilization Ratio of 0.18 for Q1 2026, up 117.02% sequentially from 0.08 in Q4 2025, and down 53.84% YoY from 0.4 in Q1 2025.
Dyadic International (DYAI) Asset Utilization Ratio (2019 - 2026) Analysis & Trends
Dyadic International has reported Asset Utilization Ratio for 8 years, with the latest figure at 0.18 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 53.84% year-over-year to 0.18 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.18 (down 53.84% YoY) and the FY2025 annual result came in at 0.09, down 76.05% from the prior year.
- Asset Utilization Ratio climbed to 0.18 in Q1 2026 per DYAI's latest filing, from 0.08 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.52 in Q2 2025 and troughed at 0.0 in Q2 2022.
- A 5-year average of 0.24 and a median of 0.25 in 2023 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio slumped 100.0% in 2022, then surged 115324.92% in 2023.
- Over 5 years, Asset Utilization Ratio stood at 0.2 in 2022, then soared by 63.78% to 0.33 in 2023, then advanced by 1.62% to 0.34 in 2024, then slumped by 74.84% to 0.08 in 2025, then surged by 117.02% to 0.18 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.18, 0.08, and 0.34 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 0.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.18 |
| Dec 31, 2025 | 0.08 |
| Sep 30, 2025 | 0.34 |
| Jun 30, 2025 | 0.52 |
| Mar 31, 2025 | 0.40 |
| Dec 31, 2024 | 0.34 |
| Sep 30, 2024 | 0.31 |
| Jun 30, 2024 | 0.15 |
| Mar 31, 2024 | 0.22 |
| Dec 31, 2023 | 0.33 |
| Sep 30, 2023 | 0.29 |
| Jun 30, 2023 | 0.29 |
| Mar 31, 2023 | 0.25 |
| Dec 31, 2022 | 0.20 |
| Sep 30, 2022 | 0.15 |
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 20.48 |
| Sep 30, 2021 | 18.39 |
| Jun 30, 2021 | 16.89 |